Company Name: |
BOC Sciences
|
Tel: |
16314854226 |
Email: |
info@bocsci.com |
Products Intro: |
Product Name:SR 2595 CAS:1415252-61-7 Purity:98% Package:1G;10G;100G Remarks:SR 2595 is an inverse agonist of PPARγ (IC50 = 30 nM) that represses both transactivation in a promoter:reporter assay and expression of the adipogenic marker fatty acid-binding protein 4 in different
|
Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
Tel: |
18818260767 |
Email: |
sales@chemegen.com |
Products Intro: |
Product Name:SR 2595 CAS:1415252-61-7 Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
Company Name: |
Energy Chemical
|
Tel: |
021-58432009 400-005-6266 |
Email: |
marketing1@energy-chemical.com |
Products Intro: |
Product Name:SR2595 >=98% (HPLC) CAS:1415252-61-7 Purity:NULL Package:1ea;25mg;5mg Remarks:NULL
|
Company Name: |
MedBioPharmaceutical Technology Inc
|
Tel: |
021-69568360 18916172912 |
Email: |
order@med-bio.cn |
Products Intro: |
Product Name:SR 2595 CAS:1415252-61-7 Purity:98% Package:5mg; 10mg; 1mg Remarks:Medbio
|
Company Name: |
TargetMol Chemicals Inc.
|
Tel: |
4008200310 |
Email: |
marketing@tsbiochem.com |
Products Intro: |
Product Name:SR 2595 CAS:1415252-61-7 Purity:98% Package:100 mg;5 mg;50 mg
|
|
| SR 2595 Basic information |
Product Name: | SR 2595 | Synonyms: | SR 2595;SR2595 >=98% (HPLC);[1,1'-Biphenyl]-2-carboxylic acid, 4'-[[5-[[[(1S)-1-[4-(1,1-dimethylethyl)phenyl]ethyl]amino]carbonyl]-2,3-dimethyl-1H-indol-1-yl]methyl]-;4'-[[5-[[[(1S)-1-[4-(1,1-dimethylethyl)phenyl]ethyl]amino]carbonyl]-2,3-dimethyl-1H-indol-1-yl]methyl]-[1,1'-biphenyl]-2-carboxylicacid | CAS: | 1415252-61-7 | MF: | C37H38N2O3 | MW: | 558.71 | EINECS: | | Product Categories: | | Mol File: | 1415252-61-7.mol | |
| SR 2595 Chemical Properties |
Boiling point | 785.4±60.0 °C(Predicted) | density | 1.13±0.1 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | ≤5mg/ml in ethanol;10mg/ml in DMSO;10mg/ml in dimethyl formamide | form | crystalline solid | pka | 3.87±0.36(Predicted) |
| SR 2595 Usage And Synthesis |
Description | SR 2595 is an inverse agonist of PPARγ (IC50 = 30 nM) that represses both transactivation in a promoter:reporter assay and expression of the adipogenic marker fatty acid-binding protein 4 in differentiating murine preadipocytes. Repression of PPARγ with SR 2595 promotes osteogenesis, as measured by calcium phosphatase deposition, in cultured human mesenchymal stem cells (MSCs). SR 2595 also increases expression of bone morphogenetic proteins BMP2 and BMP6 in MSCs. | in vitro | sr 2595 was identified as an inverse agonist of pparγ that repressed both transactivation and expression of the adipogenic marker fatty acid-binding protein 4 in differentiating murine preadipocytes. moreover, the repression of pparγ with sr 2595 promoted osteogenesis in cultured human mesenchymal stem cells (mscs), as demonstrated by calcium phosphatase deposition. in addition, sr 2595 could also increase the expression of bone morphogenetic proteins bmp2 and bmp6 in mscs [1]. | in vivo | to determine whether pharmacological pparg repression would impair insulin sensitivity, sr2595 was administered chronically to lean c57bl/6j mice. the pk properties of sr2595 were sufficient to support once daily oral dosing at 20 mg/kg. lean c57bl/6j mice treated with sr2595 showed no significant change in insulin sensitivity as measured by insulin tolerance test, nor fasting insulin levels. in addition, no change in food consumption or body weight was observed during the treatment period [1]. | IC 50 | 30 nm | references | [1] marciano, d. p.,kuruvilla, d.s.,boregowda, s.v., et al. pharmacological repression of pparγ promotes osteogenesis. nature communications 6, 1-7 (2015). |
| SR 2595 Preparation Products And Raw materials |
|